DCGI grants SII permission to manufacture Sputnik V for specific regulatory purposes

·1-min read
Representative Image
Representative Image

By Shalini Bhardwaj

New Delhi [India], June 4 (ANI): The Drug Controller General of India (DCGI) on Friday granted the approval to the Serum Institute of India (SII) for the initial manufacture of the Russian COVID-19 vaccine Sputnik V for testing, examination, and analysis purposes with certain conditions at its licensed facility in Hadapsar, Pune.

The SII has submitted an application to the DCGI in this regard on Thursday.

The Pune-based company has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia to develop Sputnik V in India.

The SII will be the Sixth company to manufacture Sputnik V India. The companies like Hetero Biopharma, Gland Pharma, Panacea Biotec, Stelis Biopharma, and Virchow Biotech will be manufacturing Sputnik V in India. (ANI)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting